Riboflavin (B2)
Research Reliability -
The activated form of Vitamin B2, essential for mitochondrial energy production, antioxidant recycling, and cellular metabolism.
Appetite
Mood
Sleep
Riboflavin (B2)
Description
Riboflavin 5-phosphate (R5P) is the coenzyme form of B2, bypassing the conversion step required by standard riboflavin and offering superior bioavailability. It is a critical component of two flavoenzymes, FAD and FMN, that power the mitochondrial electron transport chain and support fat and protein metabolism. R5P also activates other B vitamins and plays a key role in glutathione recycling, the body's primary antioxidant defense. Those with MTHFR variants may benefit especially from this activated form.
Effects
Same day
urine turns bright yellow (harmless, expected)
Weeks 2–4
for migraine-prone people, frequency may ease
Ongoing
energy metabolism support
How it Feels
The one thing you will notice is neon-yellow urine, which is normal and harmless. Beyond that, effects are subtle. Migraine sufferers are the group most likely to feel a real benefit, and that takes weeks.
Usage
Entry Dose
10mg
Standard Dose
25–50mg
Max Dose
400mg
Onset
2–4 weeks
Combinations
Pairs well with
Synergistic
Magnesium — B2 + magnesium is the most-studied combo for migraine prevention
Niacinamide (B3) — B2 converts B3 into active NAD+ and NADP+ coenzymes
5-MTHF — B2 is a cofactor for MTHFR enzyme; enhances folate cycle activation
Avoid combining
Contraindicated
Tricyclic antidepressants — long-term use may impair riboflavin absorption
High-dose iron — may interfere with riboflavin absorption when taken together
Biomarkers to Track
Subjective
(Daily)
Migraine frequency and severity
Eye fatigue or light sensitivity
Energy levels (1–10)
Objective
(Quarterly)
Plasma riboflavin level
Homocysteine (MTHFR support)
Urine color (bright yellow = active)
Very safe and water-soluble. Bright yellow urine is the only visible effect.
Almost no one.
Panicking at the neon urine (it is harmless) and expecting migraine benefit in days rather than weeks.
Moderate (some human RCTs)
Migraine-prevention evidence comes from a single, frequently-cited trial; effect size is modest and takes months to build.
Schoenen J et al. (1998). Neurology. RCT (migraine prophylaxis). PMID: 9484373.